在NSAID-Exactableerbated呼吸道疾病中,两种明显的重型2型喘转录亚型
Radosław Kacorzyk1,2, Piotr Szatkowski1, Bogdan Jakieła1
12nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.
概括
这项研究在非类固醇抗炎药物恶化呼吸道疾病 (N-ERD) 患者中确定了两种不同的严重喘亚型. 唾液GATA3表达水平可以区分这些严重的喘亚型,有助于个性化治疗策略.
科学领域:
- 呼吸系统医学 呼吸系统医学
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
背景情况:
- 非类固醇抗炎药物加剧呼吸道疾病 (N-ERD) 是一种异质的疾病.
- 患有严重喘和阿司匹林过敏症的患者表现出不同的唾液基因表达.
- 识别不同的转录亚型对于理解N-ERD至关重要.
研究的目的:
- 为了识别与阿司匹林过敏性严重喘的不同的转录亚型.
- 用无监督的集群分析来识别亚型.
- 根据临床和分子特征来比较已识别的亚型.
主要方法:
- 在27名患有严重喘和阿司匹林过敏症的患者中进行了唾液诱导 (全球喘II型倡议标准).
- 使用87个基因的转录签名进行了无监督的集群分析.
- 用临床特征和生物标志物测量来比较亚型.
主要成果:
- 确定了两个不同的亚型 (集群):集群1 (n=10) 和集群2 (n=17).
- 集群1显示GATA3表达较低,唾液中氨基酸细胞增加,巨细胞减少和前列腺素D2水平升高.
- 集群2的特点是高GATA3表达,表明T2炎症.
结论:
- 集群1表示T2炎症具有低GATA3表达;集群2显示T2炎症具有高GATA3表达.
- 唾液GATA3表达是区分N-ERD患者严重喘亚型的潜在生物标志物.
- 这些发现可能会指导N-ERD个性化治疗方法.
更多相关视频
相关概念视频
Asthma-II: Pathophysiology and Classification
4.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.6K
Asthma: Pathogenesis and Management
1.4K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.4K
Asthma-I: Introduction
3.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.6K
Antiasthma Drugs: Leukotriene Modifiers
1.9K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.9K
Adrenergic Receptors: ɑ Subtype
3.1K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.1K
Asthma-IV: Diagnostic and Management
3.2K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.2K


